TY - JOUR
T1 - Human papillomavirus shows highly variable prevalence in esophageal squamous cell carcinoma and no significant correlation to p16INK4a overexpression
T2 - A systematic review
AU - Michaelsen, Sanne Høxbroe
AU - Larsen, Christian Grønhøj
AU - Von Buchwald, Christian
PY - 2014/6
Y1 - 2014/6
N2 - INTRODUCTION:: This review investigates the role of p16 as a marker of transcriptionally active human papillomavirus (HPV) in esophageal squamous cell carcinoma (ESCC) and the regional prevalence of HPV in ESCC. METHODS:: PubMed, EMBASE, and the Cochrane Library were systematically searched with the purpose of identifying all studies published between January 1980 and July 2013 reporting both HPV and p16 results in a minimum of five human ESCC specimens. RESULTS:: Twelve studies were identified, providing data on a total of 1383 ESCC specimens collected between 1987 and 2009 from 10 different countries. HPV DNA was detected in 12.0% (n = 161) of 1347 specimens, and p16 was detected in 33.9% (n = 209) of 617 specimens. The HPV presence varied from 0% to 70% among the studies. The prevalence of p16 overexpression in HPV-positive and HPV-negative specimens demonstrated no statistically significant difference, neither for the combined data (p = 0.7507) nor for any individual study, and detection of p16 overexpression did not affect the odds of tumors being HPV positive (odds ratio = 1.0666 with 95% confidence interval 0.7040-1.6157). In a pooled analysis, the sensitivity of p16 overexpression as a marker of HPV DNA presence was 0.35, the specificity 0.67, and the positive predictive value 0.25. CONCLUSIONS:: This systematic review reports great regional variation in the prevalence of HPV in ESCC and suggests that p16 is not a reliable marker of HPV status in ESCC.
AB - INTRODUCTION:: This review investigates the role of p16 as a marker of transcriptionally active human papillomavirus (HPV) in esophageal squamous cell carcinoma (ESCC) and the regional prevalence of HPV in ESCC. METHODS:: PubMed, EMBASE, and the Cochrane Library were systematically searched with the purpose of identifying all studies published between January 1980 and July 2013 reporting both HPV and p16 results in a minimum of five human ESCC specimens. RESULTS:: Twelve studies were identified, providing data on a total of 1383 ESCC specimens collected between 1987 and 2009 from 10 different countries. HPV DNA was detected in 12.0% (n = 161) of 1347 specimens, and p16 was detected in 33.9% (n = 209) of 617 specimens. The HPV presence varied from 0% to 70% among the studies. The prevalence of p16 overexpression in HPV-positive and HPV-negative specimens demonstrated no statistically significant difference, neither for the combined data (p = 0.7507) nor for any individual study, and detection of p16 overexpression did not affect the odds of tumors being HPV positive (odds ratio = 1.0666 with 95% confidence interval 0.7040-1.6157). In a pooled analysis, the sensitivity of p16 overexpression as a marker of HPV DNA presence was 0.35, the specificity 0.67, and the positive predictive value 0.25. CONCLUSIONS:: This systematic review reports great regional variation in the prevalence of HPV in ESCC and suggests that p16 is not a reliable marker of HPV status in ESCC.
KW - Esophageal squamous cell carcinoma
KW - Human papillomavirus
KW - Predictive Value of Tests
KW - Carcinoma, Squamous Cell/chemistry
KW - Prevalence
KW - Papillomaviridae/genetics
KW - Biomarkers/analysis
KW - Esophageal Neoplasms/chemistry
KW - Humans
KW - DNA, Viral/analysis
KW - Cyclin-Dependent Kinase Inhibitor p16/analysis
KW - Papillomavirus Infections/complications
U2 - 10.1097/JTO.0000000000000166
DO - 10.1097/JTO.0000000000000166
M3 - Journal article
C2 - 24787962
AN - SCOPUS:84901595219
SN - 1556-0864
VL - 9
SP - 865
EP - 871
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 6
ER -